Anti-CD20 treatment and neutrophil function in central nervous system demyelinating diseases

被引:1
作者
Balazs, Irina [1 ,2 ]
Horvath, Angela [1 ,2 ]
Heschl, Bettina [3 ]
Khalil, Michael [3 ]
Enzinger, Christian [3 ]
Stadlbauer, Vanessa [1 ,2 ]
Seifert-Held, Thomas [3 ,4 ]
机构
[1] Med Univ Graz, Dept Internal Med, Div Gastroenterol & Hepatol, Auenbruggerpl 15, A-8036 Graz, Austria
[2] Ctr Biomarker Res Med, Stiftingtalstr 5, A-8010 Graz, Austria
[3] Med Univ Graz, Dept Neurol, Auenbruggerpl 22, A-8036 Graz, Austria
[4] Hosp Murtal, Dept Neurol, Gaaler Str 10, A-8720 Knittelfeld, Austria
关键词
Multiple sclerosis; NMODS; Rituximab; Neutrophils; NET formation; MULTIPLE-SCLEROSIS; B-CELLS; AUTOIMMUNE; MECHANISMS;
D O I
10.1016/j.jneuroim.2023.578136
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: A contribution of neutrophil granulocytes to the pathogenesis of multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) is recognized. Anti-CD20 treatments applied in these diseases are associated with infectious complications and neutropenia. No data is available about functional characteristics of neutrophils obtained from patients with anti-CD20 treatments.Methods: In neutrophils isolated from 13 patients with anti-CD20 treatment (9 MS, 4 NMOSD), 11 patients without anti-CD20 treatment (9 MS, 2 NMOSD) and 5 healthy controls, we analyzed chemotaxis, production of reactive oxygen species (ROS), phagocytosis, and formation of neutrophil extracellular traps (NET) in vitro. Results: Chemotaxis and ROS production were found unchanged between patients with and without anti-CD20 treatment or between patients and healthy controls. We found a higher proportion of non-phagocytosing cells in patients without anti-CD20 treatment compared to patients with anti-CD20 treatment and healthy controls. As compared to healthy controls, a higher proportion of neutrophils from patients without anti-CD20 treatments underwent NET formation, either unstimulated or stimulated with phorbol 12-myristate 3-acetate for 3 h. In about half of patients with anti-CD20 treatment (n = 7), NET formation of unstimulated neutrophils occurred already within 20 min of incubation. This was not observed in patients without anti-CD20 treatment and healthy controls. Conclusion: Anti-CD20 treatment in MS and NMOSD patients does not alter chemotaxis and ROS production of neutrophils in vitro but might restore their impaired phagocytosis in these diseases. Our study reveals a predisposition to early NET formation in vitro of neutrophils obtained from patients with anti-CD20 treatment. This may contribute to associated risks of neutropenia and infections.
引用
收藏
页数:5
相关论文
共 34 条
[1]   Autoimmune neutropenia in adults [J].
Akhtari, Mojtaba ;
Curtis, Brian ;
Waller, Edmund K. .
AUTOIMMUNITY REVIEWS, 2009, 9 (01) :62-66
[2]   Polymorphonuclear Cell Functional Impairment in Relapsing Remitting Multiple Sclerosis Patients: Preliminary Data [J].
Allizond, Valeria ;
Scutera, Sara ;
Rossi, Silvia ;
Musso, Tiziana ;
Crocilla, Cristina ;
Cavalla, Paola ;
Trebini, Claudia ;
Marra, Elisa Simona ;
Cuffini, Anna Maria ;
Banche, Giuliana .
PLOS ONE, 2015, 10 (06)
[3]   B lymphocytes in neuromyelitis optica [J].
Bennett, Jeffrey L. ;
O'Connor, Kevin C. ;
Bar-Or, Amit ;
Zamvil, Scott S. ;
Hemmer, Bernhard ;
Tedder, Thomas F. ;
von Buedingen, H. -Christian ;
Stuve, Olaf ;
Yeaman, Michael R. ;
Smith, Terry J. ;
Stadelmann, Christine .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2015, 2 (03) :e104
[4]  
Brinkmann Volker, 2010, J Vis Exp, DOI 10.3791/1724
[5]   Neutrophil perversion in demyelinating autoimmune diseases: Mechanisms to medicine [J].
Casserly, Courtney S. ;
Nantes, Julia C. ;
Hawkins, Ryder F. Whittaker ;
Vallieres, Luc .
AUTOIMMUNITY REVIEWS, 2017, 16 (03) :294-307
[6]   The B cell helper side of neutrophils [J].
Cerutti, Andrea ;
Puga, Irene ;
Magri, Giuliana .
JOURNAL OF LEUKOCYTE BIOLOGY, 2013, 94 (04) :677-682
[7]  
Graf J., 2021, NEUROL NEUROIMMUNOL, V8
[8]   Targeting B Cells to Modify MS, NMOSD, and MOGAD Part 1 [J].
Graf, Jonas ;
Mares, Jan ;
Barnett, Michael ;
Aktas, Orhan ;
Albrecht, Philipp ;
Zamvil, Scott S. ;
Hartung, Hans-Peter .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (01)
[9]   Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry [J].
Hallin, Erik I. ;
Serkland, Trond Traetteberg ;
Myhr, Kjell-Morten ;
Torkildsen, Oivind Grytten ;
Skrede, Silje .
JOURNAL OF MASS SPECTROMETRY AND ADVANCES IN THE CLINICAL LAB, 2022, 25 :53-60
[10]   A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma [J].
Han, Xiaohong ;
Zhang, Mingzhi ;
Wang, Huaqing ;
Zhang, Qingyuan ;
Li, Wei ;
Hao, Miaowang ;
Gao, Yuhuan ;
Jin, Jie ;
Ren, Hanyun ;
Tang, Yun ;
Hong, Xiaonan ;
Ke, Xiaoyan ;
Su, Hang ;
Gui, Lin ;
Luo, Jianmin ;
Xie, Liangzhi ;
Gai, Wenlin ;
Shi, Yuankai .
CHINESE JOURNAL OF CANCER RESEARCH, 2022, 34 (06) :601-611